ABTC 1202: Phase 1 Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma
CTO - IRB 8454
Cancer - Brain
Principal Investigator: Tommy Mikkelsen, MD
The trial studies the side effects and best dose of WEE1 inhibitor MK-1775 when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme. MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving MK-1775 together with radiation therapy and temozolomide may be an effective treatment for glioblastoma multiforme.
Patients must have a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of glioblastoma completed and signed by a pathologist. Patients must have a Karnofsky score of greater than or equal to 60%.